Alcohol withdrawal syndrome: treatment with trazodone.
Central monoaminergic pathways dysfunction has been shown in the alcohol withdrawal syndrome of experimental animals: noradrenergic hyperfunction and serotonin transmission impairment is suggested by many studies. Trazodone is a new psychotropic drug which has a marked norepinephrine receptor blocking power; moreover, it inhibits serotonin reuptake and was fully effective in the treatment of man's withdrawal syndrome (17 alcoholic inpatients). The good therapeutical results make it conceivable that monoaminergic pathways dysfunction has an important pathophysiological role in the alcohol withdrawal syndrome of man also.
D000328:Adult; D001921:Brain / Q000187:drug effects; D000431:Ethanol / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D018377:Neurotransmitter Agents / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*; D014196:Trazodone / Q000494:pharmacology / Q000627:therapeutic use*
D018377:Neurotransmitter Agents; D010879:Piperazines; D000431:Ethanol; D014196:Trazodone